Covid Antibody Titers in Cancer Patients Following Vaccination with ChAdOx1 nCOV-19 Vaccine

 

 Permissions and Reprints

Abstract

Covid-19 has led to significant mortality worldwide, with an increased risk in cancer patients. Vaccination provides significant protection against the infection. The study focuses on the immunogenicity and effectiveness of ChAdOx1 nCoV-19 vaccine in cancer patients within a real-world setting. Blood samples for measuring Covid antibody titers against the receptor binding domain were collected according to a convenient sparse sampling strategy in a real-world setting, with the days of the collection coinciding with their hospital appointment. The antibody titers between different groups were analyzed descriptively. A total of 56 patients were enrolled in the study. There was no apparent effect in antibody titers between patients with solid tumors and hematological malignancies (mean ± standard deviation [SD]: 36.80 ± 41.18 vs. 52.02 ± 26.27), among patients who were undergoing chemotherapy, immunotherapy, or local therapy (mean ± SD: 42.50 ± 44.46 vs. 50.06 ± 51.39 vs. 28.70 ± 25.03), and in patients with up to 90 days and more than 90 days' interval between their last treatment and date of vaccination (mean ± SD: 38.96 ± 42.66 vs. 40.51 ± 38.65). Additionally, there were only 2/56 patients with breakthrough infection, which points out the effectiveness of this vaccine in cancer patients. The ChAdOx1 nCoV-19 vaccine has activity in cancer regardless of the tumor type, type of treatment, or time from the last treatment.

Authors' Contribution

AC was responsible for complete data collection and drafting of the manuscript. BS was involved in analyzing the data, drafting the manuscript, and preparing for publication. AS was involved in data collection. PC, UG, BP, and VB were responsible for analyzing the samples. CD and VG were involved in conceiving and designing the study, interpreting the data, and reviewing the manuscript critically. All the authors read and approved the final version of the manuscript.

^# Asare joint first authors.

Publication History

Article published online:
07 August 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 Madhi SA, Baillie V, Cutland CL. et al; NGS-SA Group, Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384 (20) 1885-1898
  CrossrefPubMedGoogle Scholar
• 2 Chopra M, Jain A, Chhabra S. et al. Short research communication anti-spike antibody response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) vaccine in patients with B-cell and plasma cell malignancies and hematopoietic cell transplantation recipients. Indian J Hematol Blood Transfus 2022; 38 (04) 745-749
  CrossrefPubMedGoogle Scholar
• 3 Voysey M, Clemens SAC, Madhi SA. et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397 (10269): 99-111
  CrossrefPubMedGoogle Scholar
• 4 Folegatti PM, Ewer KJ, Aley PK. et al; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396 (10249): 467-478
  CrossrefPubMedGoogle Scholar
• 5 MoHFW. Home. Accessed September 25, 2022 at: https://www.mohfw.gov.in/
  Google Scholar
• 6 Desai A, Gainor JF, Hegde A. et al; COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 2021; 18 (05) 313-319
  CrossrefPubMedGoogle Scholar
• 7 Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. European Society for Medical Oncology. The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate. Ann Oncol 2021; 32 (05) 579-581
  CrossrefPubMedGoogle Scholar
• 8 Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol 2021; 14 (01) 38
  CrossrefPubMedGoogle Scholar
• 9 Barrière J, Carles M, Audigier-Valette C. et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article. Eur J Cancer 2022; 162: 182-193
  CrossrefPubMedGoogle Scholar
• 10 Guven DC, Sahin TK, Kilickap S, Uckun FM. Antibody responses to COVID-19 vaccination in cancer: a systematic review. Front Oncol 2021; 11: 759108
  CrossrefPubMedGoogle Scholar
• 11 Singh AK, Phatak SR, Singh R. et al. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: a 6-month longitudinal cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Diabetes Metab Syndr 2022; 16 (02) 102424
  CrossrefPubMedGoogle Scholar
• 12 Teeyapun N, Luangdilok S, Pakvisal N. et al. Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: a prospective, multicenter observational study. EClinicalMedicine 2022; 52: 101608
  CrossrefPubMedGoogle Scholar
• 13 Jayadevan R, Shenoy R, Anithadevi T. COVID-19 third wave experience in India, a survey of 5971 adults. Epidemiology 2022; (e-pub ahead of print). DOI: 10.1101/2022.04.26.22274273.
  CrossrefGoogle Scholar